SARS CoV 2 News and Research

RSS

Study suggests enhanced phosphorylation and increased abundance of SARS-CoV-2 nucleocapsid protein provide selective advantage

Researchers have been investigating the phosphorylation of the nucleocapsid protein.

27 Jan 2022

French project takes an extra step in the development of nasal vaccine candidate against COVID-19

The development of a protein vaccine candidate for nasal administration has taken another step. Led by the BioMAP research team, from the Infectiology and Public Health (ISP) joint research unit run by INRAE and the Université de Tours, this project, supported by the Ministry of Higher Education, Research and Innovation, and accompanied by the ANRS | Maladies infectieuses émergentes, is moving up a gear.

27 Jan 2022

Risk of long COVID-19 predicted by immunoglobulin signature

In a new study published in the journal Nature Communications, scientists studied COVID-19 patients and found that the immunoglobulin (Ig) signature can predict the risk of PACS independently of the time point of blood sampling.

27 Jan 2022

Strict COVID-19 lockdown policies helped reduce air pollution levels and death rates in Europe

Strict COVID-19 lockdown policies such as workplace closures in European cities reduced levels of air pollution and the number of associated deaths, according to new estimates published in Nature's Scientific Reports.

27 Jan 2022

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

A new study, published on the medRxiv preprint server, focused on the production of human CD4+ T cell lines (TCLs), reactive to either S or M protein, and analyzed if the S and M structural proteins had intrinsic differences in driving antigen-specific CD4+ T cell responses.

27 Jan 2022

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

In a study conducted at the Florida International University, USA, scientists have investigated the impact of spike receptor-binding domain (RBD) mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant on its interaction with human angiotensin-converting enzyme 2 (ACE2).

26 Jan 2022

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

In the recently published study in The Lancet, first-authored by Dr. Sue Ann Costa Clemens from the University of Oxford in the United Kingdom and the University of Siena in Italy, a comprehensive analysis has been pursued on the immunogenicity and safety of both homologous and heterologous boosting after receiving the inactivated vaccine CoronaVac.

26 Jan 2022

Urinary proteomic COV50 marker accurately predicts adverse COVID-19 outcomes

The researchers described COV50, a urinary biomarker, that can predict death and disease progression in COVID-19.

26 Jan 2022

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Researchers assess the probability of T-cell apoptosis in patients with severe COVID-19 who were admitted to the hospital.

26 Jan 2022

Microbiome 'profiling' may help identify people at risk of long COVID

The make-up of the gut microbiome may be linked to a person's risk of developing 'long COVID' many months after initial infection with SARS-CoV-2, the virus responsible for COVID-19 infection, suggests research published online in the journal Gut.

26 Jan 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

New research on SARS-CoV-2 Omicron and care home residents

Researchers find a reduced risk of hospitalizations and deaths in long term care facility residents infected with SARS-CoV-2 Omicron variant.

26 Jan 2022

Online survey highlights the struggles of females with long COVID

Researchers assess the experiences and consequences of long COVID in women’s lives through an online intervention.

26 Jan 2022

Language used to describe 'long COVID' can impact patient outcomes

Researchers utilize an online experimental platform to explore the effect of different messages about long COVID on expectations of illness outcomes.

26 Jan 2022

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.

26 Jan 2022

SARS CoV 2 News and Research

Study suggests enhanced phosphorylation and increased abundance of SARS-CoV-2 nucleocapsid protein provide selective advantage

French project takes an extra step in the development of nasal vaccine candidate against COVID-19

Risk of long COVID-19 predicted by immunoglobulin signature

Strict COVID-19 lockdown policies helped reduce air pollution levels and death rates in Europe

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

Urinary proteomic COV50 marker accurately predicts adverse COVID-19 outcomes

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Microbiome 'profiling' may help identify people at risk of long COVID

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

New research on SARS-CoV-2 Omicron and care home residents

Online survey highlights the struggles of females with long COVID

Language used to describe 'long COVID' can impact patient outcomes

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

Exploring hematological alterations in COVID-19 patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News